Prof Kaye Williams BSc PhD

Chair Experimental Therapeutics

Full contact details
View graph of relations


Outside of running a successful research group and teaching highly motivated students on the MPharm programme, many of my academic leadership and management roles within the University of Manchester are focused upon the promotion and development of research. Specific contributions are made via the following:

  • Deputy Director CRUK RadNET Manchester
  • Pre-clinical lead for oncology imaging within the Manchester Cancer Research Centre. 
  • Deputy director Imaging@Manchester: Preclinical
  • Co-chair of the University of Manchester Preclinical Imaging Executive (PrIME)
  • Head of Pharmaceutical Sciences, Division of Pharmacy and Optometry

My additional roles focus on equality and diversity and in staff training and development. I chaired the Athena Swan Self Assessment team in Manchester Pharmacy School and was the MPS representative on the previous faculty's Equality and Diversity committee. I am staff training and development lead for Pharmacy and work with colleagues towards developing cases for promotion both within and outwith my division. 



Professor Kaye Williams is Leader of the Hypoxia and Therapeutics Group within the Division of Pharmacy and Optometry at the University of Manchester. Kaye joined DPO in November 1996. Following back-to-back Research Associate and Research Fellow positions funded by the MRC, she gained tenure in January 2006, and was promoted to Chair in Experimental Therapeutics and Imaging in August 2012. Her research focuses on the tumour microenvironment, investigating therapeutic targets, vascular biology and molecular interactions that influence tumour response to radiotherapy. Kaye also leads pre-clinical imaging development within the Manchester Cancer Research Centre, and has leadership for preclinical imaging within Imaging@Manchester. Externally, she has had significant roles in the NCRI Clinical and Translational Radiotherapy Research Working Group, in particular through association with the RadCom initiative that aimed to expedite novel drug radiation combinations into clinical trial. She continues to provide leadership in this area via the CRUK Drug-Radiotherapy Working Group. She is part of the team that secured £16.5 million for the University of Manchester towards infrastructure funding in radiation related research via the CRUK RadNET initiative and currently acts as Deputy Director of CRUK RadNET Manchester. 

Kaye was awarded the British Association for Cancer Research/AstraZeneca Frank Rose Young Scientist Award in 2005.


  • 1997 - PhD Faculty of Medicine - University of Manchester
  • 1993 - BSc (Hons) Molecular Biology - First Class, School of Biological Sciences, University of Manchester

Memberships of committees and professional bodies


  • Committee member Association for Radiation Research 2016-
  • National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research (CTRad) Executive group member
  • Co-chair CRUK RadNET Drug Radiation Combination Working Group

Member of

  • British Association for Cancer Research
  • European Association for Cancer Research
  • American Association for Cancer Research
  • Association of Radiation Research
  • Radiation Research Society

Research Beacons, Institutes and Platforms

Sustainable Development Goals

Related information


Prize: Prize (including medals and awards)

View all prizes (1)